MY CONJECTURE:Maybe the EU adoption of the FDA approved SAP(agreed upon with NWBO,I assume.But not yet disclosed) is very recent.Disclosed to we, the unwashed , today , here on IHUB, by ATL.Looks like Germany has not had time to change from the prior endpoints to the new ones.See below.So, net, net, the EU is the first of the 4 regulators to have announced that they will adopt the SAP agreed to by NWBO and the FDA(but not yet announced).This SAP plays to Dc Vax L's strength ,long term survival. A bit FUBAR and bassackwards; nonetheless,A BREAKTHROUGH in terms of getting DC Vax L approved by the major global regulatory authorities.My guess is that all 4 regulatiors are on board with this one SAP.Next stop, $3-5 billion in GBM revenues for NWBO.Then , the question becomes, is DC Vax a new and proprietary cancer immunotherapy platform.Will Dc vax direct really work on 13 different solid tumors?
ATL's fabulous discovery,10/8/20:"Post # 315347 of 315667
In the EU Clinical Trial register, it shows that the primary endpoint for the DCVax-L trial is Overall Survival (OS), not PFS (see Section E.2.1 and E.2.2).
Also, the clinical trial register says that OS primary endpoint will be evaluated in October 2020 (see Section E.5.1.1).
In Section E.5.2, it says that the "second secondary" endpoint is PFS. It also says that the second secondary endpoint will be evaluated in October 2020: Post # 315405 of 315667 "
Somebody else found this:"The German link is still showing the old endpoints:
Market Data 
Markets 
AI
